Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NephroGenex Inc.

www.nephrogenex.com

Latest From NephroGenex Inc.

Pyridoxamine Petition Paints Better Option As Dietary Ingredient Than IND

ViGuard Health says in a petition that with two IND programs for studies of pyridoxamine's potential therapeutic use formally withdrawn, FDA should rescind its 2009 decision that it did not qualify as a dietary ingredient.

Dietary Supplements Ingredients

Biotech Bankruptcies: BIND and NephroGenex Weigh Options

Once-prosperous biotechs are now seeking strategic alternatives including the selling off of all of their assets now that they've failed to acquire the funds they need to move forward.

Business Strategies Cancer

Deals Shaping The Medical Industry, December 2015

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in November 2015.

BioPharmaceutical Medical Device

Biopharma In 2014: Early Access Gains Offset Taxation, Pricing Woes

The year was marked by record levels of biopharma M&A activity and a strong IPO market. Measures designed to deliver early access to new medicines continued to advance on both sides of the Atlantic, while pricing came in for renewed attention as new, highly effective but extremely expensive products reached the market.

BioPharmaceutical Pricing Strategies
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Renal System
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • NephroGenex Inc.
  • Senior Management
  • Pierre Legault, CEO
    John P Hamill, CFO
    J. Wesley Fox, PhD, Pres. & CSO
    Jaikrishna Patel, MD, CMO
  • Contact Info
  • NephroGenex Inc.
    Phone: (609) 986-1780
    3200 Beechleaf Ct.
    Ste. 900
    Raleigh, NC 27604
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register